Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Hansa Biopharma AB ( (SE:HNSA) ) has provided an update.
Hansa Biopharma AB has announced a directed share issue of approximately 10 million common shares to institutional investors, with the proceeds intended for general corporate purposes, including ongoing phase III trials for imlifidase and supporting its European business operations. Additionally, the company is restructuring its debt with NovaQuest, which includes a set-off of USD 14.9 million of debt in exchange for new shares, and revised payment terms extending mandatory cash payments until June 2027. This strategic financial maneuver aims to strengthen Hansa’s capital structure and enhance its operational capabilities, positioning the company for continued growth and stability in the competitive biopharmaceutical industry.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a biopharmaceutical company based in Lund, Sweden, primarily focused on developing innovative immunomodulatory treatments. The company is known for its work on imlifidase, a drug aimed at enabling kidney transplants in highly sensitized patients, and it operates within the European market.
Average Trading Volume: 157,282
Current Market Cap: SEK1.66B
Learn more about HNSA stock on TipRanks’ Stock Analysis page.